If you took Zantac for heartburn in the 1980s, 1990s, or even as recently as 2019, you may have been exposed to a known carcinogen. The drug’s active ingredient, ranitidine, was found to break down into NDMA, a chemical linked to liver, bladder, and stomach cancer. What started as a routine medicine became one of the most complicated and contested toxic tort cases in American history. Understanding what happened with Zantac helps explain how pharmaceutical toxic reactions lead to liability, and why proving harm is so hard.

Here is the simple story. Ranitidine is inherently unstable. Under normal storage conditions or after years on a shelf, the molecule can degrade. One of the breakdown products is NDMA, or N-nitrosodimethylamine. That compound is a known genotoxic carcinogen, meaning it can damage DNA directly. In 2019, an online pharmacy called Valisure ran its own tests and found high levels of NDMA in batches of Zantac and its generics. The FDA later confirmed that contamination increased over time and at higher temperatures. The agency asked manufacturers to pull all ranitidine products from stores. That withdrawal set off a wave of lawsuits from people with cancer who had taken the drug for years.

From a legal standpoint, these cases fall under a few basic theories. The most common is failure to warn. A drug company has a duty to tell users about known or reasonably discoverable risks. If the company knew ranitidine could form NDMA, or should have known through basic stability testing, and still failed to put a warning on the label, that is negligence. Another theory is design defect. The argument here is that ranitidine itself was too dangerous because its chemical structure made NDMA formation inevitable. A safer alternative, like omeprazole or famotidine, existed. Under that logic, the design was defective, and the manufacturer should pay for the harm it caused. A third theory is breach of warranty, but that usually boils down to the same practical question: did the drug cause your injury?

That causal link is the biggest hurdle in any toxic tort case, and Zantac is a perfect example. A plaintiff cannot just show that a drug contains a carcinogen. They must show that the specific amount of carcinogen they ingested, over their specific period of use, actually caused their specific type of cancer. That is not easy. Cancer develops from many factors, including genetics, smoking, diet, and other chemical exposures. To isolate Zantac as the cause, plaintiffs rely on expert witnesses. Those experts use two main types of evidence. First, they dose-run computer models that estimate the amount of NDMA a person would have absorbed over years of daily use. Second, they cite epidemiological studies that look at large populations to see whether ranitidine users had higher rates of cancer.

This is where the litigation got messy. The science behind Zantac’s danger was real, but the dosage question was not. NDMA levels varied wildly depending on batch, storage time, temperature, and even the individual pill bottle. Some tests showed low levels, others showed very high levels. No one could say with certainty how much NDMA any given plaintiff actually consumed. Defense experts argued that the amounts were too small to increase cancer risk beyond normal background levels. Some courts agreed. In 2022, the judge managing the consolidated federal cases, known as multidistrict litigation, threw out thousands of claims. He ruled that the plaintiffs’ expert testimony on causation was not based on reliable methods. That decision did not say Zantac was safe. It said the plaintiffs had not met the legal standard of proof. This is a core principle in toxic tort law: exposure alone is not injury, and speculation is not evidence.

The Zantac cases also highlight another issue known as federal preemption. Drug companies sometimes argue that because the FDA approved their drug label, they should be shielded from state failure-to-warn claims. But preemption does not apply when a company hides risks or violates FDA requirements. In most Zantac cases, that defense failed because the companies had not reported the instability issue to the FDA. So the cases turned entirely on the science.

What does this mean for you? It shows that pharmaceutical toxic reactions are not like ordinary product accidents. A car crash gives you a broken bone, and the cause is obvious. A chemical exposure gives you cancer years later, and the cause is buried under stacks of lab data and statistics. For lawyers, winning a pharmaceutical toxic tort requires more than sympathy. It requires evidence that would hold up under peer review. For plaintiffs, it means that even a truly dangerous drug can escape liability if no one can prove which pill did the damage. For manufacturers, the lesson is clear: stability testing and honest labeling are not optional. Ignoring a known chemical breakdown product can turn a billion-dollar medication into a legal catastrophe.

The Zantac story is far from over. Some state court cases have survived where federal cases did not, and appeals continue. But the central fight remains the same. In a toxic tort case, the law does not ask if the drug could cause cancer. It asks if that drug caused this cancer. Until science gives a definitive answer, courts will keep arguing, and victims will keep waiting.